Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 480 IDR -3.23% Market Closed
Market Cap: 5.4T IDR

Relative Value

The Relative Value of one PYFA stock under the Base Case scenario is 567.53 IDR. Compared to the current market price of 480 IDR, Pyridam Farma Tbk PT is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PYFA Relative Value
Base Case
567.53 IDR
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
62
Median 3Y
1.6
Median 5Y
1.4
Industry
2.7
vs History
vs Industry
43
Median 3Y
-7.6
Median 5Y
1.4
Industry
21.5
vs History
vs Industry
22
Median 3Y
-2.5
Median 5Y
-4.8
Industry
16.7
vs History
vs Industry
36
Median 3Y
1.2
Median 5Y
1.6
Industry
23
vs History
9
vs Industry
46
Median 3Y
2.5
Median 5Y
3.2
Industry
2.3
vs History
31
vs Industry
31
Median 3Y
3.6
Median 5Y
2
Industry
2.9
vs History
12
vs Industry
15
Median 3Y
10.5
Median 5Y
5.4
Industry
5.6
vs History
vs Industry
0
Median 3Y
-47.3
Median 5Y
9.2
Industry
13.2
vs History
vs Industry
0
Median 3Y
-47.3
Median 5Y
9.2
Industry
16.6
vs History
vs Industry
8
Median 3Y
-10.5
Median 5Y
-12.3
Industry
15.8
vs History
vs Industry
7
Median 3Y
-12.3
Median 5Y
-12.3
Industry
19
vs History
44
vs Industry
57
Median 3Y
1.1
Median 5Y
1.4
Industry
2

Multiples Across Competitors

PYFA Competitors Multiples
Pyridam Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Pyridam Farma Tbk PT
IDX:PYFA
5.4T IDR 1.9 -11.2 -66.7 -66.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.2 37 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.4 158.7
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
264.6B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average P/E: 24.3
Negative Multiple: -11.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
37%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBITDA: 439.6
Negative Multiple: -66.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBIT: 1 882.9
Negative Multiple: -66.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4